Showing 6391-6400 of 7112 results for "".
- Prostaglandin D2 A Potential New Target for Alopecia Therapyhttps://practicaldermatology.com/news/20120326-prostaglandin_d2_a_potential_new_target_for_alopecia_therapy/2459832/Prostaglandin D2 (PGD2) appears to inhibit hair growth in androgenetic alopecia (AGA) and may be potential target for its treatment, new research suggests (Sci Transl Med. 4(126):126ra34). Researchers show that PG
- Skinvisible Granted Patent for UVA Absorberhttps://practicaldermatology.com/news/20120320-skinvisible_granted_patent_for_uva_absorber/2459836/Skinvisible Pharmaceuticals, Inc. has been granted a new patent for its UVA sunscreen absorber. Skinvisible's new formulation with avobenzone provides eight hours of photostability, an advantage for those who spend many hours in the sun. The ingredi
- Galderma Completes Phase 3 Rosacea Erythema Studyhttps://practicaldermatology.com/news/20120320-galderma_completes_of_phase_3_rosacea_erythema_study/2459839/Galderma Laboratories announced the completion of two independent Phase 3 clinical trials that evaluated the safety and efficacy of CD07805/47, a proprietary topical gel under investigation in patients with moderate to severe facial erythema of
- Phase 3 Trials launching for adalimumab for hidradenitis suppurativahttps://practicaldermatology.com/news/20120315-phase_3_trials_launching_for_adalimumab_for_hidradenitis_suppurativa/2459842/Two Phase 3 clinical trials are underway to evaluate the safety and efficacy of Abbott's Humira (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa (HS). The
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- FDA's 45-day TV ad reviewhttps://practicaldermatology.com/news/20120313-fdas_45-day_tv_ad_review_shot_clock_in_guidance/2459846/TV ads for most prescription drugs must be submitted to FDA for pre-review 45 days before the manufacturer intends to air them, according to an FDA draft guidance in tomorrow's Federal Register. The guidance isn't a bolt from the blue but rather a case of the agency catching up on old business – i
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by
- YBF Beauty Products Debut on Ulta.comhttps://practicaldermatology.com/news/20120307-ybf_beauty_products_debut_on_ultacom/2459853/YBF Beauty , a complete collection of makeup essentials from Stacey Schieffelin, is now available from Ulta.com . The products feature Smart Active Complex, a paraben-free formula, "enriche
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at